These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

266 related items for PubMed ID: 29050502

  • 1. First Evidence: TRAP-Induced Platelet Aggregation Is Reduced in Patients Receiving Xabans.
    Nehaj F, Sokol J, Ivankova J, Mokan M, Kovar F, Stasko J, Mokan M.
    Clin Appl Thromb Hemost; 2018 Sep; 24(6):914-919. PubMed ID: 29050502
    [Abstract] [Full Text] [Related]

  • 2. First evidence: rivaroxaban and apixaban reduce thrombin-dependent platelet aggregation.
    Sokol J, Nehaj F, Ivankova J, Mokan M, Mokan M.
    J Thromb Thrombolysis; 2018 Oct; 46(3):393-398. PubMed ID: 30039454
    [Abstract] [Full Text] [Related]

  • 3. Platelet Aggregation in Direct Oral Factor Xa Inhibitors-treated Patients With Atrial Fibrillation: A Pilot Study.
    Bánovčin P, Škorňová I, Samoš M, Schnierer M, Bolek T, Kovář F, Staško J, Kubisz P, Mokáň M.
    J Cardiovasc Pharmacol; 2017 Oct; 70(4):263-266. PubMed ID: 28708713
    [Abstract] [Full Text] [Related]

  • 4. Effect of the FXa inhibitors Rivaroxaban and Apixaban on platelet activation in patients with atrial fibrillation.
    Steppich B, Dobler F, Brendel LC, Hessling G, Braun SL, Steinsiek AL, Deisenhofer I, Hyseni A, Roest M, Ott I.
    J Thromb Thrombolysis; 2017 May; 43(4):490-497. PubMed ID: 28316004
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. TRAP-induced platelet aggregation is enhanced in cardiovascular patients receiving dabigatran.
    Olivier CB, Weik P, Meyer M, Weber S, Anto-Michel N, Diehl P, Zhou Q, Geisen U, Bode C, Moser M.
    Thromb Res; 2016 Feb; 138():63-68. PubMed ID: 26610745
    [Abstract] [Full Text] [Related]

  • 7. Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system.
    Villines TC, Ahmad A, Petrini M, Tang W, Evans A, Rush T, Thompson D, Oh K, Schwartzman E.
    Eur Heart J Cardiovasc Pharmacother; 2019 Apr 01; 5(2):80-90. PubMed ID: 30500885
    [Abstract] [Full Text] [Related]

  • 8. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration.
    Borne RT, O'Donnell C, Turakhia MP, Varosy PD, Jackevicius CA, Marzec LN, Masoudi FA, Hess PL, Maddox TM, Ho PM.
    BMC Cardiovasc Disord; 2017 Sep 02; 17(1):236. PubMed ID: 28865440
    [Abstract] [Full Text] [Related]

  • 9. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB, Skjøth F, Søgaard M, Kjældgaard JN, Lip GY, Larsen TB.
    BMJ; 2017 Feb 10; 356():j510. PubMed ID: 28188243
    [Abstract] [Full Text] [Related]

  • 10. Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin.
    Wong PC, Jiang X.
    Thromb Haemost; 2010 Aug 10; 104(2):302-10. PubMed ID: 20589316
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation.
    Yoshimura A, Iriki Y, Ichiki H, Oketani N, Okui H, Maenosono R, Namino F, Miyata M, Ohishi M.
    J Cardiol; 2017 Jan 10; 69(1):228-235. PubMed ID: 27131792
    [Abstract] [Full Text] [Related]

  • 12. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Yao X, Abraham NS, Sangaralingham LR, Bellolio MF, McBane RD, Shah ND, Noseworthy PA.
    J Am Heart Assoc; 2016 Jun 13; 5(6):. PubMed ID: 27412905
    [Abstract] [Full Text] [Related]

  • 13. An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants.
    Deitelzweig S, Bruno A, Trocio J, Tate N, Gupta K, Lin J, Lingohr-Smith M.
    Curr Med Res Opin; 2016 Jun 13; 32(3):573-82. PubMed ID: 26652179
    [Abstract] [Full Text] [Related]

  • 14. Does proton pump inhibition change the on-treatment anti-Xa activity in xabans-treated patients with atrial fibrillation? A pilot study.
    Bolek T, Samoš M, Škorňová I, Stančiaková L, Staško J, Korpallová B, Galajda P, Kubisz P, Mokáň M.
    J Thromb Thrombolysis; 2019 Jan 13; 47(1):140-145. PubMed ID: 30288664
    [Abstract] [Full Text] [Related]

  • 15. Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation.
    Rillig A, Lin T, Plesman J, Heeger CH, Lemes C, Metzner A, Mathew S, Wissner E, Wohlmuth P, Ouyang F, Kuck KH, Tilz RR.
    J Cardiovasc Electrophysiol; 2016 Feb 13; 27(2):147-53. PubMed ID: 26464027
    [Abstract] [Full Text] [Related]

  • 16. Effects of direct oral anticoagulants on lupus anticoagulant assays in a real-life setting.
    Antovic A, Norberg EM, Berndtsson M, Rasmuson A, Malmström RE, Skeppholm M, Antovic J.
    Thromb Haemost; 2017 Aug 30; 117(9):1700-1704. PubMed ID: 28640321
    [Abstract] [Full Text] [Related]

  • 17. Does atorvastatin therapy change the anti-Xa activity in xabans-treated patients with atrial fibrillation?
    Škorňová I, Samoš M, Bolek T, Stančiaková L, Vádelová Ľ, Galajda P, Staško J, Kubisz P, Mokáň M.
    Pharmacol Res Perspect; 2021 May 30; 9(3):e00730. PubMed ID: 33984191
    [Abstract] [Full Text] [Related]

  • 18. Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data.
    Kohsaka S, Murata T, Izumi N, Katada J, Wang F, Terayama Y.
    Curr Med Res Opin; 2017 Nov 30; 33(11):1955-1963. PubMed ID: 28857611
    [Abstract] [Full Text] [Related]

  • 19. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care.
    Vinogradova Y, Coupland C, Hill T, Hippisley-Cox J.
    BMJ; 2018 Jul 04; 362():k2505. PubMed ID: 29973392
    [Abstract] [Full Text] [Related]

  • 20. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
    Coleman CI, Peacock WF, Bunz TJ, Alberts MJ.
    Stroke; 2017 Aug 04; 48(8):2142-2149. PubMed ID: 28655814
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.